| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
Protein hydrolyzates (silk) target cellular and extracellular components involved in skin and tissue maintenance. Their biological activity is primarily attributed to their ability to provide essential amino acids and small peptides that serve as building blocks for collagen and elastin synthesis in the skin. In wound healing applications, silk protein hydrogels promote cell migration and proliferation. The smaller molecular weight peptides are more penetrating and moisturizing to skin and hair compared to larger protein powders. They also function as antistatic agents, moisturizers, and hair conditioners in cosmetic formulations.
|
|---|---|
| ln Vitro |
In vitro, protein hydrolyzates from silk have demonstrated the ability to promote cell migration and proliferation in wound healing models. The amino acid components act as natural moisturizing factors that can bind moisture to the skin surface. In cell culture applications, silk protein hydrolyzates provide a biocompatible substrate that supports cell adhesion and growth. Their low molecular weight peptides exhibit enhanced penetration into the stratum corneum, contributing to their skin-conditioning effects. These properties make them valuable for studying extracellular matrix biology, peptide bioactivity, and functional materials in vitro.
|
| ln Vivo |
In vivo, protein hydrolyzates from silk have been studied for their wound healing and tissue regeneration properties. Silk protein hydrogels are utilized in wound healing applications due to their biocompatibility and ability to promote cell migration and proliferation. In animal models, these hydrolyzates have shown effectiveness in replenishing lost protein that causes dryness and damage. They are also used in biomedical applications as biodegradable materials that support tissue repair. Their non-toxic and non-irritating nature makes them suitable for in vivo applications in both research and clinical settings.
|
| Enzyme Assay |
The in vitro biological activity of protein hydrolyzates is typically assessed using cell culture models. Fibroblasts or keratinocytes are cultured in media supplemented with various concentrations of the hydrolyzates (e.g., 0.1-10 mg/mL) for 24-72 hours. Cell proliferation is measured using MTT or BrdU incorporation assays. Cell migration is assessed using scratch wound healing assays, where the rate of wound closure is measured microscopically. Collagen synthesis can be evaluated by ELISA or Western blot. The hydrolyzates are dissolved in culture media and sterilized by filtration before use.
|
| Cell Assay |
Cellular assays for protein hydrolyzates are performed using skin-related cell lines such as human dermal fibroblasts (HDF) or HaCaT keratinocytes. Cells are cultured in DMEM or appropriate media supplemented with 10% FBS at 37°C in 5% CO₂. Cells are treated with the hydrolyzates at concentrations ranging from 0.1-10 mg/mL for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Collagen and elastin production are measured by ELISA or immunocytochemistry. The hydrolyzates are typically dissolved in sterile water or PBS and filter-sterilized before addition to cell cultures.
|
| Animal Protocol |
In vivo studies for protein hydrolyzates are conducted in rodent wound healing models. Full-thickness excisional wounds are created on the dorsal skin of mice or rats. Hydrolyzate formulations (e.g., hydrogels or creams) are applied topically to the wounds daily. Wound closure is monitored by digital photography and planimetry. At various time points, wounds are harvested for histological analysis (H&E, Masson's trichrome), immunohistochemistry for collagen and growth factors, and measurement of tensile strength. Biocompatibility is assessed by observing inflammation, infection, or adverse reactions at the wound site.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for protein hydrolyzates are not typically reported as these are complex mixtures rather than single compounds. However, the hydrolysis process breaks down the protein into smaller peptides, enhancing their bioavailability and digestibility. The smaller molecular weight of the hydrolyzates (compared to intact silk protein) allows for better absorption and penetration into tissues. In cosmetic applications, the hydrolyzates are designed for topical delivery, where they exert their moisturizing and skin-conditioning effects locally. Systemic pharmacokinetics would depend on the specific peptide composition and route of administration.
|
| Toxicity/Toxicokinetics |
Protein hydrolyzates from silk are considered non-toxic, non-irritating, and biodegradable. In cosmetic and biomedical applications, they have demonstrated excellent safety profiles. Silk protein hydrogels are biocompatible and do not elicit significant inflammatory responses in wound healing models. The hydrolyzates are generally recognized as safe for topical use in cosmetic formulations. For research applications, standard safety assessments including cytotoxicity testing and skin irritation studies are recommended. As with any protein-based material, potential allergenicity should be considered, although silk proteins are typically hypoallergenic.
|
| Additional Infomation |
Protein hydrolyzates from silk are fibrous proteins produced by silkworms and spiders that can be incorporated into cosmetics and biomedical materials. Their biocompatibility, biodegradability, and moisturizing properties make them attractive for wound dressings, tissue engineering scaffolds, and cosmetic formulations. In cosmetic products, they act as antistatic agents, moisturizers, and hair conditioners. No clinical trials or regulatory approvals exist for therapeutic use. For research use only.
|
| CAS # |
96690-41-4
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| Synonyms |
Silk amino acid Silk hydrolyzates silk hydrolysatesProtein hydrolyzates, silk
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
